FIGURE 2.

Dose-dependent reduction of pericyte-associated BBB leakage and MMP-9 activity with intracortical L-NIL injection. (A) Representative example of vehicle injected control mouse (same example as in panel of Figure 1F). (B,C) Representative example of mice receiving low-dose (3.8 μM) and high-dose (19 μM) L-NIL. (D) Effect of L-NIL on number of BBB leakage occurring at pericyte soma and non-soma locations. Pericyte soma leakage sites per hour per 0.007 mm³: 3.125 ± 0.398 (vehicle), 2.750 ± 0.453 (3.8 μM L-NIL), 1.125 ± 0.227 (19 μM L-NIL); No pericyte soma leakage sites per hour per 0.007 mm³: 1.625 ± 0.183 (vehicle), 1.750 ± 0.250 (3.8 μM L-NIL), 1.750 ± 0.164 (19 μM L-NIL). One-way ANOVA with Bonferroni post hoc test; F(5, 42) = 6.373, *p = 0.045 overall, ***p = 0.0004 (vehicle soma vs. 19 μM L-NIL soma), **p = 0.0052 (3.8 μM L-NIL soma vs. 19 μM L-NIL soma); N = 8 mice (one region imaged per mouse) for each treatment group. Data is presented as mean ± S.E.M. (E) Proportion of leakage sites with FITC-gelatin cleavage at pericyte soma and non-soma locations with and without L-NIL. Each bar shows FITC-gelatin positive leakage sites over total number of leakage sites observed.